MedRhythms this week said it received FDA breakthrough device designation for its digital therapeutic device that treats chronic stroke walking deficits. The company uses sensors, music and software to create evidence-based, neurologic interventions to measure and improve walking. The device is currently being studied in a randomized controlled trial to evaluate the impact of the […]
Neurological
Welcome to MassDevice's Neurological Hub, your resource for the latest news in the neurological device space. Stay informed about the innovations and business news shaping the neurological industry.
🧠 Narrow your focus with these categories:
Neuromodulation/Neurostimulation | Bioelectronic Medicine | Pain Management | Brain-Computer Interfaces
Here are the top neurological device features from MassDevice and its sister publications (and scroll down to read the latest cardiology device news from MassDevice):
+ 7 brain-computer interface companies you need to know
+ Brain breakthroughs: Aprinoia Therapeutics’ harnesses AI and strategic partnerships to propel neurodegenerative disease research
+ Natalizumab and PML: The complex dance of benefit and risk for MS
Latest Neurological News
CEO Ryan explains how Cala Health is building bioelectronic medicine business
In this week’s episode of DeviceTalks Weekly, Tom Salemi, editorial director of DeviceTalks events and content, visits with Renee Ryan, the CEO of neuromodulation startup Cala Health. Ryan came to Cala from the venerable medtech investor Johnson & Johnson Development Corp., where she made over 15 investments helping to create companies including Auris Surgical, Cala […]
CereVasc closes $43.9m Series A
Hydrocephalus treatment developer CereVasc announced today that it closed an expanded Series A financing round, raising a total of $43.9 million. The Perceptive Xontogeny Venture (PXV) Fund and ATON Partners led the funding round, according to a news release. CereVasc intends to use the raised proceeds to support the first-in-human clinical trial for its eShunt […]
Study finds delays in seeking stroke treatment amid COVID-19
Ischemic stroke patients are showing up to the hospital an average of 160 minutes later during the COVID-19 pandemic than during a similar timeframe in 2019, according to a new study. The delay is affecting both stroke survival and recovery, add stroke surgeons from the Society of NeuroInterventional Surgery (SNIS). The first study to confirm […]
FDA approves remote to check out Axonics neuromod device before MRI
Axonics Modulation Technologies (NSDQ:AXNX) announced today that it received FDA pre-market approval for its SmartMRI wireless patient remote control. Irvine, Calif.-based Axonics’ wireless control for SmartMRI is used with its implantable r-SNM (sacral neuromodulation) systems that treat urinary and bowel dysfunction. The new control allows for a simplified full-body MRI process by offering a technician a […]
ReWalk Robotics posts COVID-19-affected Q1 losses
ReWalk Robotics (NSDQ:RWLK) shares ticked up slightly today despite first-quarter results that came up short of the consensus forecast. The Yokneam Illit, Israel–based robotic walking assistance company posted losses of $3.8 million, or -37¢ per share, on sales of $760,000 for the three months ended March 31, 2020, for a 4% bottom-line gain on a sales […]
Silk Road Medical closes allotment option
Silk Road Medical (NSDQ:SILK) announced that underwriters fully exercised and closed on additional options to purchase shares in a stock offering. The offering of more than 6.8 million shares included the exercise of the option to purchase more than 1 million additional shares at the public offering price of $39 per share. Silk Road Medical […]
Balt wins IDE approval to start STEM trial
Balt announced that it received FDA investigation device exemption (IDE) for its trial for the treatment of chronic sub-dural hematoma. The Squid trial for the embolization of the middle meningeal artery (STEM) is a prospective, randomized controlled trial for Balt’s Squid liquid embolic device as a minimally invasive treatment option for the neurological disease. Irvine, […]
PhotoPharmics wins FDA breakthrough device designation for noninvasive Parkinson’s treatment device
PhotoPharmics recently said it received FDA breakthrough device designation for noninvasive Specialized Phototherapy Device to treat Parkinson’s disease. The device is administered through a prescription from a doctor and is an adjunct therapy for treating Parkinson’s disease, according to the company. It is designed to be used with standard dopaminergic therapy and can be used […]
Neuronetics, Obalon Therapeutics get PPP loans
Neuronetics (NSDQ:STIM) and Obalon Therapeutics (NSDQ:OBLN) are the latest companies to announce that they entered into loans under the Paycheck Protection Program (PPP). The U.S. Small Business Association administers the PPP as part of the Coronavirus Aid, Relief and Economic Security (CARES) Act. Under the PPP, 75% of the loan proceeds must be used for payroll purposes, […]
Nevro raising more than $300m through public offering, convertible senior notes
Nevro (NYSE:NVRO) announced today that it priced concurrent underwritten public offerings of more than 1.6 million common stock shares, as well as convertible senior notes, to raise more than $300 million. The offering of 1,625,000 total shares of common stock at a price of $84.00 per share is slated to bring gross proceeds of approximately $136.5 […]